{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:51:04Z","timestamp":1788187864468,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>We generated an optimized COVID-19 vaccine candidate based on the modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein, termed MVA-CoV2-S(3P). The S(3P) protein was expressed at higher levels (2-fold) than the non-stabilized S in cells infected with the corresponding recombinant MVA viruses. One single dose of MVA-CoV2-S(3P) induced higher IgG and neutralizing antibody titers against parental SARS-CoV-2 and variants of concern than MVA-CoV2-S in wild-type C57BL\/6 and in transgenic K18-hACE2 mice. In immunized C57BL\/6 mice, two doses of MVA-CoV2-S or MVA-CoV2-S(3P) induced similar levels of SARS-CoV-2-specific B- and T-cell immune responses. Remarkably, a single administration of MVA-CoV2-S(3P) protected all K18-hACE2 mice from morbidity and mortality caused by SARS-CoV-2 infection, reducing SARS-CoV-2 viral loads, histopathological lesions, and levels of pro-inflammatory cytokines in the lungs. These results demonstrated that expression of a novel full-length prefusion-stabilized SARS-CoV-2 S protein by the MVA poxvirus vector enhanced immunogenicity and efficacy against SARS-CoV-2 in animal models, further supporting MVA-CoV2-S(3P) as an optimized vaccine candidate for clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2021.824728","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:13:11Z","timestamp":1643278391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection"],"prefix":"10.3389","volume":"12","author":[{"given":"Patricia","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"L\u00e1zaro-Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"S\u00e1nchez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Astorgano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Luczkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Arriaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3","article-title":"A New Coronavirus Associated With Human Respiratory Disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nat"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2100509","DOI":"10.2807\/1560-7917.ES.2021.26.24.2100509","article-title":"Increased Transmissibility and Global Spread of SARS-CoV-2 Variants of Concern as at June 2021","volume":"26","author":"Campbell","year":"2021","journal-title":"Euro Surveill"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708820","article-title":"Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk","volume":"12","author":"Strafella","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41467-020-20321-x","article-title":"Stabilizing the Closed SARS-CoV-2 Spike Trimer","volume":"12","author":"Juraszek","year":"2021","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a Multi-Antigenic SARS-CoV-2 Vaccine Candidate Using a Synthetic Poxvirus Platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02260-20","article-title":"COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice","volume":"95","author":"Garcia-Arriaza","year":"2021","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257191","article-title":"Vaccinia Virus-Based Vaccines Confer Protective Immunity Against SARS-CoV-2 Virus in Syrian Hamsters","volume":"16","author":"Kulkarni","year":"2021","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2026785118","DOI":"10.1073\/pnas.2026785118","article-title":"One or Two Injections of MVA-Vectored Vaccine Shields Hace2 Transgenic Mice From SARS-CoV-2 Upper and Lower Respiratory Tract Infection","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2021.02.001","article-title":"A Modified Vaccinia Ankara Vector-Based Vaccine Protects Macaques From SARS-CoV-2 Infection, Immune Pathology, and Dysfunction in the Lungs","volume":"54","author":"Routhu","year":"2021","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2026207118","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and Efficacy of the COVID-19 Candidate Vector Vaccine MVA-SARS-2-S in Preclinical Vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0826","article-title":"Structure-Based Design of Prefusion-Stabilized SARS-CoV-2 Spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Sci"},{"key":"B17","article-title":"[The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained With the Parenteral Vaccination and Behavior in Organisms With a Debilitated Defence Mechanism (Author\u2019s Transl)]","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl Bakteriol B"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.2.923-933.2000","article-title":"Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison With the Western Reserve Strain and Advantages as a Vaccine","volume":"74","author":"Ramirez","year":"2000","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0220","article-title":"Cross-Neutralization Activity Against SARS-CoV-2 is Present in Currently Available Intravenous Immunoglobulins","volume":"12","author":"Diez","year":"2020","journal-title":"Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03246-12","article-title":"High, Broad, Polyfunctional, and Durable T Cell Immune Responses Induced in Mice by a Novel Hepatitis C Virus (HCV) Vaccine Candidate (MVA-HCV) Based on Modified Vaccinia Virus Ankara Expressing the Nearly Full-Length HCV Genome","volume":"87","author":"Gomez","year":"2013","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03418-13","article-title":"A Novel Poxvirus-Based Vaccine, MVA-CHIKV, is Highly Immunogenic and Protects Mice Against Chikungunya Infection","volume":"88","author":"Garcia-Arriaza","year":"2014","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e00363\u201318","DOI":"10.1128\/JVI.00363-18","article-title":"Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates Against Ebola Virus Expressing GP and VP40 Proteins","volume":"92","author":"Lazaro-Frias","year":"2018","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17385","DOI":"10.1038\/s41598-018-35724-6","article-title":"A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice","volume":"8","author":"Perez","year":"2018","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 Neutralizing Antibodies Using a CPE-Based Colorimetric Live Virus Micro-Neutralization Assay in Human Serum Samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J Med Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009576","article-title":"Dc\/L-SIGN Recognition of Spike Glycoprotein Promotes SARS-CoV-2 Trans-Infection and can be Inhibited by a Glycomimetic Antagonist","volume":"17","author":"Thepaut","year":"2021","journal-title":"PloS Pathog"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 Novel Coronavirus (2019-Ncov) by Real-Time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill"},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/vaccines8010070","article-title":"Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B","volume":"8","author":"Perez","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","article-title":"A Mouse Model of SARS-CoV-2 Infection and Pathogenesis","volume":"28","author":"Sun","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012395","article-title":"Immunogenic Profiling in Mice of a HIV\/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions","volume":"5","author":"Garcia-Arriaza","year":"2010","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nat"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0762","article-title":"Evaluation of K18-Hace2 Mice as a Model of SARS-CoV-2 Infection","volume":"103","author":"Moreau","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 Infection of Human ACE2-Transgenic Mice Causes Severe Lung Inflammation and Impaired Function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.845531","article-title":"Clinical Applications of Attenuated MVA Poxvirus Strain","volume":"12","author":"Gomez","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola Virus Disease: Current Vaccine Solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.74.11.5091-5100.2000","article-title":"Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein can be Stabilized by an Intermolecular Disulfide Bond Between the Gp120 and Gp41 Subunits","volume":"74","author":"Sanders","year":"2000","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and Structures of a Rationally Designed Prefusion MERS-CoV Spike Antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15701","DOI":"10.1038\/s41598-018-34171-7","article-title":"Stabilized Coronavirus Spikes are Resistant to Conformational Changes Induced by Receptor Recognition or Proteolysis","volume":"8","author":"Kirchdoerfer","year":"2018","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e02648\u201320","DOI":"10.1128\/mBio.02648-20","article-title":"Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model","volume":"12","author":"Amanat","year":"2021","journal-title":"mBio"},{"key":"B41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","article-title":"mRNA-Based SARS-CoV-2 Vaccine Candidate CVnCoV Induces High Levels of Virus-Neutralising Antibodies and Mediates Protection in Rodents","volume":"6","author":"Rauch","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0190821","DOI":"10.1128\/mBio.01908-21","article-title":"Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX\/COVID-12-HEXAPRO (Patria), in Pigs","volume":"12","author":"Lara-Puente","year":"2021","journal-title":"mBio"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.057299-0","article-title":"New Vaccinia Virus Promoter as a Potential Candidate for Future Vaccines","volume":"94","author":"Di Pilato","year":"2013","journal-title":"J Gen Virol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/vaccines7040208","article-title":"An MVA Vector Expressing HIV-1 Envelope Under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV\/AIDS Vaccine Design","volume":"7","author":"Perez","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.036","article-title":"Correlation of Immunogenicities and In Vitro Expression Levels of Recombinant Modified Vaccinia Virus Ankara HIV Vaccines","volume":"26","author":"Wyatt","year":"2008","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e02107\u201320","DOI":"10.1128\/JCM.02107-20","article-title":"Neutralizing Antibodies Correlate With Protection From SARS-CoV-2 in Humans During a Fishery Vessel Outbreak With a High Attack Rate","volume":"58","author":"Addetia","year":"2020","journal-title":"J Clin Microbiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26241","article-title":"Antibody Responses Against SARS-CoV-2 in COVID-19 Patients","volume":"93","author":"Liu","year":"2021","journal-title":"J Med Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.08.001","article-title":"Treatment of Coronavirus Disease 2019 Patients With Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality","volume":"190","author":"Salazar","year":"2020","journal-title":"Am J Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"Hlh Across Speciality Collaboration UK. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-0305-6","article-title":"In the Eye of the COVID-19 Cytokine Storm","volume":"20","author":"Vaninov","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/vaccines9040324","article-title":"BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic Hace2 Mice Against COVID-19","volume":"9","author":"Ji","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3035-9","article-title":"A Single-Dose Live-Attenuated YF17D-Vectored SARS-CoV-2 Vaccine Candidate","volume":"590","author":"Sanchez-Felipe","year":"2021","journal-title":"Nat"},{"key":"B53","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"B55","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations With Age and Disease Severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive Immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an Inactivated Vaccine Candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Sci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/ijmr.IJMR_4431_20","article-title":"Comparison of the Immunogenicity & Protective Efficacy of Various SARS-CoV-2 Vaccine Candidates in non-Human Primates","volume":"153","author":"Mukhopadhyay","year":"2021","journal-title":"Indian J Med Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0402-6","article-title":"T Cell Responses in Patients With COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.824728\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:13:14Z","timestamp":1643278394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.824728\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2021.824728"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.824728","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"article-number":"824728"}}